Navigation Links
Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals
Date:12/9/2009

SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today that on December 3, 2009, Anesiva entered into an Asset Purchase Agreement which assigned its rights under the Revised License Agreement with PowderJect Technologies, Ltd., dated November 30, 2009, and sold certain assets related to Zingo to Powder Pharmaceuticals, Inc. (Powder Pharma), a British Virgin Island LLC, and Lee's Pharmaceuticals (HK) Limited (Lee's Pharma), a British Virgin Island LLC. Under the terms of the Asset Purchase Agreement, the total purchase price of the Zingo-related assets was approximately $2.7 million with payment contingent on the delivery of certain assets to Powder Pharma and Lee's Pharma.

Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, is an easy-to-administer, single-use, needle-free system that reduces the pain associated with peripheral intravenous (IV) line placements and blood draws in children three to 18 years of age and with blood draws for adults.

About Anesiva

Anesiva seeks to be a leader in the development and commercialization of novel pharmaceutical products for pain management. Anesiva's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for the management of acute pain following orthopedic surgeries. Adlea has been shown in clinical trials to provide extended pain relief after only a single administration in multiple indications for site-specific, acute and chronic, moderate-to-severe pain.

Forward-Looking Statements

Except for historical information, this press release may be deemed to contain "forward-looking" statements. Words such as "seek" and similar expressions are intended to identify such forward-looking statements.
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
2. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
3. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
4. Anesiva Defines Regulatory Pathway for Adlea with FDA
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
7. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
8. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
9. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
10. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
11. Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Jan. 4, 2012   Unigene Laboratories, Inc. (OTCBB: ... manufacture and development of peptide-based therapeutics, announced that Ashleigh ... corporate overview at the Biotech Showcase™ 2012 in San ... a.m. PT (2:30 p.m. ET).  Mr. Palmer,s presentation will include ...
... Group, an international generic pharmaceuticals company, today announced ... Food & Drug Administration to market Methylphenidate Hydrochloride ... 40mg.  Actavis has first-to-file exclusivity on the 20mg, ... has commenced.  Methylphenidate Hydrochloride Extended-Release ...
Cached Medicine Technology:Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9 2Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity 2
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... cancers are small cell lung cancers (SCLC), which ... However, researchers at Virginia Commonwealth University Massey Cancer ... leading to this resistance that may lead to ... mediating B-cell lymphoma 2 (Bcl-2) family proteins, which ... their function, this family of proteins can trigger ...
(Date:4/22/2014)... Bethesda, MD, April 22, 2014: The Association for ... The Journal of Molecular Diagnostics on ... the baccalaureate and master,s levels of education. The ... (MLS) Curriculum Task Force of the AMP Training ... the critical need of educating future medical laboratory ...
(Date:4/22/2014)... Working with mice and rabbits, Johns Hopkins scientists have ... and breakdown, successfully preventing the development of atherosclerosis, the ... number-one cause of death among humans. The condition develops ... renders them stiff, narrowed and hardened, greatly reducing their ... and the brain. , In a series of experiments, ...
(Date:4/22/2014)... . , Reactive ... mode of action is complex: In low concentrations they ... at high concentrations they can cause "oxidative stress", which ... signaling unfolds in single cells and organelles in real-time, ... by the teams of LMU Professor Martin Kerschensteiner and ...
Breaking Medicine News(10 mins):Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2
... than in for-profit residences, review finds , WEDNESDAY, Aug. ... care than for-profit facilities, say Canadian researchers who reviewed ... , Forty studies found that non-profit nursing homes provided ... for-profit homes delivered better care. The remaining studies had ...
... , , FRIENDSWOOD, Texas, Aug. ... develops, manages and owns faith-based senior living facilities, today announced the ... development of a new senior living facility in the Houston, Texas ... $10 million senior living facility in Katy, Texas, should be available ...
... , , , NASHVILLE, ... payment cycle management solutions, today announced the implementation of its ... Group. The Sentinel Group, a recognized leader in healthcare fraud ... 5, 2009. , , The Sentinel ...
... NANJING, China, Aug. 5 /PRNewswire-Asia/ -- ... manufacturer and supplier of branded generic and,innovative anti-cancer pharmaceuticals ... 2009 second quarter results on Monday, August 17, 2009,after ... executive,officer, Jinsheng Ren, and chief financial officer, Frank Zhigang ...
... INDIANAPOLIS, Aug. 5 In the midst of the down economy, ... worse - forcing them to make difficult sacrifices to afford medications ... On Aug. 1, 2009, Lilly USA adjusted the income ... enrollment of eligible patients with incomes at or less than 300 ...
... , HACKENSACK, N.J., Aug 5 ReGen Biologics, a ... regarding its Menaflex collagen meniscus implant that were made in a ... party unaffiliated with the company. ReGen was unaware of ... on the Internet. The statements made in the release do ...
Cached Medicine News:Health News:Not-For-Profit Nursing Homes Fare Better in Studies 2Health News:TrinityCare Senior Living Announces Further Expansion in Houston Area 2Health News:TrinityCare Senior Living Announces Further Expansion in Houston Area 3Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 2Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 3Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 4Health News:Simcere Pharmaceutical Group to Announce 2009 Second Quarter Earnings on Monday, August 17, 2009 2Health News:Lilly Broadens Income Eligibility for Patient Assistance Programs 2Health News:Lilly Broadens Income Eligibility for Patient Assistance Programs 3Health News:ReGen Biologics Clarifies Recent Press about the Menaflex Device 2
Acetate Plate Sealers 100/Box...
... Microseal 'B' seals provide an adhesive-based sealing ... The aggressive adhesive layer ensures secure sample ... and tight sealing during thermal cycling when ... lid. The perforated end-tabs can be removed ...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
Inquire...
Medicine Products: